Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.

PURPOSE: Anti-vascular endothelial growth factor therapy enhances the activity of radiotherapy in experimental models, and bevacizumab has therapeutic activity in patients with metastatic colorectal cancer. EXPERIMENTAL DESIGN: Twenty-two patients with locally advanced inoperable colorectal carcino...

Full description

Bibliographic Details
Main Authors:	Koukourakis, M, Giatromanolaki, A, Sheldon, H, Buffa, F, Kouklakis, G, Ragoussis, I, Sivridis, E, Harris, A
Format:	Journal article
Language:	English
Published:	2009

Similar Items

EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
by: N. Z. Sherman, et al.
Published: (2015-02-01)

Inclusion of vasculature-related variables in the Dukes staging system of colon cancer.
by: Koukourakis, M, et al.
Published: (2005)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
by: Jiang C, et al.
Published: (2018-09-01)

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
by: Alessandro Ottaiano, et al.
Published: (2021-09-01)

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy
by: Jay S. Detsky, et al.
Published: (2018-01-01)

High DLL4 expression in tumour-associated vessels predicts for favorable radiotherapy outcome in locally advanced squamous cell head-neck cancer (HNSCC).
by: Koukourakis, M, et al.
Published: (2013)

Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy
by: Koukourakis, MI, et al.
Published: (2009)

Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
by: Koukourakis, M, et al.
Published: (2006)

The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis
by: Hung-Ming Chen, et al.
Published: (2014-09-01)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008-03-01)

Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature
by: Yusuke Fujii, et al.
Published: (2018-03-01)

Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas.
by: Giatromanolaki, A, et al.
Published: (2010)

Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia.
by: Koukourakis, M, et al.
Published: (2010)

Expression of phosphorylated (activated) receptors of vascular endothelial growth factor (VEGFR2/KDR) in colorectal cancer
by: Giatromanolaki, A, et al.
Published: (2007)

Intravitreal bevacizumab
by: Bakulesh M Khamar
Published: (2018-01-01)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015-12-01)

Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer.
by: Koukourakis, M, et al.
Published: (2006)

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
by: Kunpeng Fang, et al.
Published: (2024-02-01)

Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizumab in Ocular Complications of Intravitreal Bevacizuma
by: Kanwal Zareen Abbasi
Published: (2016-03-01)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
by: Ran Jin, et al.
Published: (2023-06-01)

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
by: Jubb, A, et al.
Published: (2010)

Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
by: Koukourakis, M, et al.
Published: (2004)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
by: Toshimitsu Tanaka, et al.
Published: (2022-08-01)

Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
by: Zhuo Ye, et al.
Published: (2015-08-01)

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab
by: Toshiaki Yoshimoto, et al.
Published: (2020-03-01)

Cyclophilin A: An Independent Prognostic Factor for Survival in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab and Chemotherapy
by: Diana Cornelia Moisuc, et al.
Published: (2024-01-01)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
by: Manmeet S. Ahluwalia, et al.
Published: (2023-09-01)

SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy
by: Koukourakis, M, et al.
Published: (2018)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-01-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-06-01)

Bevacizumab in recurrent WHO grades II–III glioma
by: Soufyan Annakib, et al.
Published: (2023-07-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer
by: Loïg Vaugier, et al.
Published: (2021-01-01)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
by: Masaaki Miyo, et al.
Published: (2020-07-01)

Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.
by: Giatromanolaki, A, et al.
Published: (2007)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
by: Marie Mayenga, et al.
Published: (2023-07-01)

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
by: Min Yan, et al.
Published: (2024-03-01)

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer
by: Apostolos Papachristos, et al.
Published: (2020-05-01)